Archan Ruparel

Archan Ruparel_Economist_Expert_Life Sciences_Charles River Associates

Archan Ruparel is a principal in the Life Sciences Practice at CRA. His experience includes a variety of life sciences, healthcare, general antitrust, and commercial strategy work. Mr. Ruparel has worked on reverse payment litigation, antitrust investigations and litigation, and merger clearance before the Federal Trade Commission (FTC) and Department of Justice (DOJ). His life sciences experience includes the assessment of damages in commercial disputes and intellectual property disputes; market definition and antitrust; commercially reasonable efforts cases; nutritional labelling; and policy analysis involving health technology assessment, Medicare, Medicaid, and 340B. Mr. Ruparel has also assisted healthcare companies and counsel on complex strategic questions involving economic analysis, auctions, and game theory. Prior to joining CRA, Mr. Ruparel was with the Bureau of Economics of the FTC.

Selected Engagements

  • 01
    ANDA challenge - Shire, Sanofi-Aventis, and Firazyr
    Shire, Sanofi-Aventis and Firazyr CRA consultants advised counsel to Shire Orphan Therapies, LLC (Shire) and Sanofi-Aventis Deutschland GMBH (Sanofi-Aventis)...
    View engagement
  • 02
    GlaxoSmithKline/Novartis/Eli Lilly Merger
    CRA economists advised Linklaters and Freshfields Bruckhaus Deringer, counsel to Novartis, throughout a three-part, $23 billion merger with GSK. Led by...
    View engagement
  • 03
    CRA addresses U.S. government healthcare programs and pharmaceutical pricing in False Claims Act suit
    In this whistleblower suit, a relator alleged Bristol-Myers Squibb Co. (“BMS”) violated the False Claims Act and various state claims. The suit alleged that...
    View engagement